– USA, CA – ChromaDex Corp. (NASDAQ: CDXC), an integrated, science-based, nutraceutical company, today announced the appointment of Frank Jaksch as Executive Chairman of the Board of Directors, effective June 22, 2018, succeeding Stephen Allen will retire at the end of his current term.
About Frank Jaksch
Frank Jaksch is a co-founder of the Company and has served as the CEO from 2000 to January 2012, and again as CEO since June 2012. Mr. Jaksch has also served as a member of the Board since February 2000. Mr. Jaksch will continue to be an active part of the executive management team on strategic and scientific advice and guidance, and new product development,ent and represent the Company in its relations with trade associations and others in the industry. “In just the last few years, we have seen an explosion in the amount of scientific research around NIAGEN® which is incredibly important to the consumers’ understanding of healthy aging and the role our TRU NIAGEN® product plays in that process,” said Frank Jaksch. “We have had a very successful transition to the TRU NIAGEN consumer product business and we are still in the early stages of this tremendous opportunity. I firmly believe this is the right time to make these changes, as the Company continues to increase its presence in the globmarketplaceace.”
“We are thrilled that both the Board and the Company will continue to benefit from Frank’s immense scientific knowledge and decades of experience in the nutraceutical industry as he continues to work alongside the business, industry, and science thought leaders on our Scientific Advisory Board,” said Steve Allen.
ChromaDex also announced the appointment of current President and COO, Rob Fried to the role of CEO, effective after June 22, 2018, succeeding Frank Jaksch as CEO.
“Over the last year, under Rob’s leadership, ChromaDex has evolved from an ingredient company to a global, consumer brand organization focused on developing and marketing products and technologies that improve how people age,” said Steve Allen, “and the Board of Directors thanks Frank for his years of leadership and Frank’s commitment to collaborate with Rob during this period to ensure a smooth transition.”
“In 2017, we made progress in our organizational shift, bringing new and diversified expertise into the organization and launching TRU NIAGEN in the U.S. and Hong Kong. I look forward to continuing to work with the talented people at ChromaDex to build on our momentum and broaden the body of clinical research around NIAGEN. We will continue to focus on expanding our distribution into international markets, leveraging our robust intellectual property, and deploying our strong balance sheet to deliver substantial global growth in sales of TRU NIAGEN,” said Rob Fried.
In addition, ChromaDex announced that the Board of Directors has appointed Kurt Gustafson, a director of ChromaDex since 2016, as Lead Independent Director, effective after the 2018 Annual Meeting of Stockholders. Mr. Gustafson will also continue to be the Chairman of the Audit Committee.
“I look forward to working with Frank and the rest of the board to guide the Company towards its mission of healthy aging during this important phase of growth,” said Kurt Gustafson.
About ChromaDex
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER.
For more information: https://www.chromadex.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
